Elizabeth Jaffe

Mar 22, 2017

The American Association for Cancer Research has elected Elizabeth Jaffe as its president for 2017-2018. Jaffe is currently a chair and member of the National Cancer Advisory Board for the National Cancer Institute, and co-chair of the NCI Blue Ribbon Panel for the National Cancer Moonshot Initiative. She is also the deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, the associate director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, professor of oncology and professor of pathology at Johns Hopkins School of Medicine, and an active staff member in oncology at Johns Hopkins Hospital.

More Like This

Oct 13, 2017

Fred Hirsch

Biocept said that Fred Hirsch has joined its clinical advisory board. Hirsch is a professor of medicine and pathology at the University of Colorado Cancer Center.

Oct 11, 2017

Thomas Grogan

Thomas Grogan has joined the board of directors of ReadCoor. He is professor emeritus of pathology at the University of Arizona College of Medicine and a scientific advisor to Ventana Medical Systems, which he founded, and Roche Tissue Diagnostics. 

Oct 11, 2017

Tom Civik

Tom Civik has been appointed as chief commercial officer of Foundation Medicine and will start his new position in mid November. Most recently, he was a vice president and franchise leader at Genentech, where he was responsible for several oncology products. Earlier, he held various commercial positions at Sanofi-Synthelabo. Civik holds a BA from St. Norbert College and a master's degree in business administration from the Kellogg School of Management at Northwestern University.

Oct 10, 2017

Andrea Bodnar

Andrea Bodnar has joined the Gloucester Marine Genomics Institute as its first scientific director. Bodnar recently served as a senior scientist in the molecular lab of the Bermuda Institute of Ocean Science, and she previously held senior scientist posts in the oncology department at Hoffman-La Roche and at Geron. She will lead the non-profit institute's genomics-driven marine research efforts.

Oct 10, 2017

Greg Yap

Greg Yap is joining Menlo Ventures as a partner to lead investments in health, medical, and life science technologies. Yap was most recently an entrepreneur-in-residence at Illumina Ventures, where he focused on new genomics investments, and also co-founded and served as CEO of PyrAmes, a digital health company. Previously Yap was CEO and co-founder of protein analysis firm Biodesy. He has also held senior roles at Roche/Ventana and Affymetrix.

Oct 10, 2017

John Kenny

John Kenny has been appointed CEO of Meridian Bioscience, effective Oct. 9. He replaces John Kraeutler who is stepping down to become executive chairman. Kraeutler announced in May his plans to resign from the company as CEO. Kenny also was appointed to Meridian's board, effective Oct. 9. Kenny was most recently senior vice president, general manager, North America at Siemens Healthcare. He has also held executive level roles at Becton Dickinson, Leica Biosystems, and Quest Diagnostics.

Oct 09, 2017

California Precision Medicine Advisory Committee

California Gov. Edmund "Jerry" Brown has created the Governor's Advisory Committee on Precision Medicine and name some well-known figures to the 14-member panel. The committee will advise the governor's office on all matters related to precision medicine and make recommendations for statewide policy. Founding members are: 

  • Tomás Aragón, health officer of the City and County of San Francisco
  • Atul Butte, principal investigator of the California Initiative to Advance Precision Medicine at UC San Francisco
  • John Carpten, chair of the Department of Translational Genomics at the University of Southern California Keck School of Medicine
  • Jay Gellert, former president and CEO of Health Net
  • Kim Goodwin, author of "Designing for the Digital Age"
  • Stephen Lockhart, chief medical officer of Sutter Health
  • Kelsey Martin, dean of the David Geffen School of Medicine at UCLA
  • Mary Maxon, associate laboratory director for biosciences at Lawrence Berkeley National Laboratory
  • Jessica Mega, chief medical officer of Verily Life Sciences
  • Jill Mesirov, associate vice chancellor for computational health at UC San Diego School of Medicine
  • Frederick Meyers, associate dean for precision medicine at UC Davis Health
  • Arnold Milstein, director of the Clinical Excellence Research Center at Stanford University
  • Hakan Sakul, vice president of diagnostics at Pfizer
  • Sue Siegel, CEO of GE Ventures. 
Oct 05, 2017

Mark Lewis

Mark Lewis has become CEO of Swift Biosciences, replacing Tim Harkins. Most recently, he held senior vice president roles in product development, general management, and customer support at Illumina. Previously, Lewis held R&D, commercial, and general management roles at various other companies, including BD Biosciences, Molecular Dynamics, Nycomed-Amersham, and Beckman Instruments. He holds a BA in biology from the University of California, San Diego.

Oct 03, 2017

Alan Copperman

Alan Copperman has joined health information firm Sema4 as its chief medical officer. Copperman is director of the division of reproductive endocrinology and infertility, and vice chairman of the department of obstetrics, gynecology, and reproductive science at the Icahn School of Medicine at Mount Sinai. He also is managing partner at Reproductive Medicine Associates of New York. 

Oct 03, 2017

Jeffrey Rona

Jeffrey Rona has resigned from his position as CFO of Great Basin Scientific, effective October 6, 2017.

Oct 03, 2017

Paul Eros

Novacyt has appointed Paul Eros as commercial director, effective Nov. 1. Eros joins Novacyt from DiaSorin, where he was VP of molecular marketing for more than five years. He has also worked for Becton Dickinson and Roche Diagnostics

Oct 03, 2017

Jeffery Luber

Atlas Genetics announced today that Jeffrey Luber has been appointed CEO and John Clarkson, current founding CEO, will become Executive Chairman. Mr. Luber joins the board with experience in the life sciences industry, including roles in both public and private companies. Most recently, he led the return to growth and sale of Good Start Genetics to Invitae. Prior to this, Luber was CEO of Exact Sciences, where he executed its turnaround and strategic transaction with Genzyme. 

Oct 02, 2017

Doug Fisher, Jeffrey Cossman

Precipio has elected Doug Fisher and Jeffrey Cossman to its board in order to fill existing vacancies. Fisher will serve on Precipio's audit committee and compensation committee. Cossman will serve on the company's compensation committee and will chair the nominating and corporate governance committee. 

Fisher is currently executive-in-resident at venture capital firm InterWest Partners, where he has worked since March 2009. He is also chief business officer at Sera Prognostics. Cossman is founder of the United States Diagnostic Standards, where he also served as CEO and chairman. Prior to that, he was CSO and a member of the board of The Critical Path Institute and as medical director of Gene Logic. 

Sep 29, 2017

Michael Epplen

Michael Epplen has been promoted to president of Sunquest Information Systems. Epplen had been serving as chief operating officer of Sunquest as well as president of Atlas Medical, which Sunquest parent company Roper Technologies acquired two years ago. He previously spent five years as CEO of Data Innovations, another company that Roper bought in 2015.

Sep 29, 2017

Timothy Ring and David Melcher

Becton Dickenson announced today that Timothy Ring and David Melcher have joined its board of directors. Ring has served as chairman and CEO of Bard since August 2003. He previously joined Bard in 1992 and has served as VP of human resources, group VP of Bard International, and in additional roles. Ring is also a director of Quest Diagnostics, a trustee for the New Jersey Health Foundation, and a board member for the Advanced Medical Technology Association. Melcher has been president and CEO of the Aerospace Industries Association since 2015. Prior to AIA, Melcher was president and CEO of Exelis, a spinoff of ITT Corporation. In addition to being a director for Bard, Melcher is also a member of the Federal Aviation Administration's NextGen Advisory Committe, providing advice on policy-level issues for US aviation modernization.  

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.